(600594)"Guizhou Yibai Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 600594 · · 12 pages · Chinese
Summary by 6ix AI
The report includes unaudited financial statements such as the consolidated balance sheet, income statement, and cash flow statement. It also highlights changes in major accounting data and financial indicators, along with non-recurring profit and loss items. The company assures the accuracy and completeness of the report's content, taking legal responsibility for any misrepresentation.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Guizhou Yibai Pharmaceutical Co. Ltd. on 6ix
Earlier from Guizhou Yibai Pharmaceutical
- Announcement on Resolutions of the 2nd Meeting of the 9th Board of Directors
- Announcement on the Selection of Products in the Second Round of Follow-Up Centralized Procurement by the National Alliance for Chinese Patent Medicine Procurement
- Announcement on the Receipt of the "Administrative Penalty Notice" from Guizhou Provincial Drug Administration
- Semi-annual Performance Forecast for 2026
- Announcement on Inclusion of the Company's Pharmaceutical Products in the "National Essential Medicines List (2026 Edition)"
Follow Guizhou Yibai Pharmaceutical into a list and get an email when it puts out news.
Follow Guizhou Yibai Pharmaceutical